Natera is a rapidly growing genetic testing and diagnostics company with proprietary bioinformatics and molecular technology. Natera’s team of PhDs and engineers is dedicated to refining novel molecular genome assays and complex statistical algorithms to determine the likelihood of a wide range of serious genetic conditions with best-in-class accuracy and coverage. Natera’s goal is to change the management of genetic disease worldwide, giving patients and providers essential health information.


back to top

Natera was founded in 2004.


back to top

As of December 31, 2021, Natera had 2,670 employees.

back to top

Natera went public on July 1, 2015 at $18.00 per share.


back to top

Our underwriters were Morgan Stanley & Co. LLC, Cowen and Company, LLC, Piper Jaffray & Co., Robert W. Baird & Co. Incorporated, and Wedbush Securities Inc.


back to top

All of Natera’s financial publications are available here.

back to top

Natera is listed on the Nasdaq Global Select Market under the ticker symbol NTRA.


back to top

The current and historical stock price of NTRA can be found here. For more current information and historical prices, visit our Stock Information pages.

back to top

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
(800) 662-7232


back to top

The CUSIP number for Natera’s common stock is 632307104.


back to top

Natera has never declared or paid any cash dividend on its capital stock and does not anticipate paying any dividends in the foreseeable future.

back to top

Natera’s fiscal year ends December 31.


back to top

Ernst & Young LLP.


back to top

Please visit our Contact page.

back to top